Verrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company's trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.
Verrica Pharmaceuticals (NASDAQ:VRCA) announced its quarterly earnings, reporting an EPS of ($0.51), missing the consensus estimate of ($0.43). However, the company's revenue of $5.09 million surpassed analysts' expectations of $4.52 million. The stock currently holds an average "Hold" rating from analysts with an average price target of $17.00, and institutional investors own 42.45% of the company's stock.
Verrica Pharmaceuticals announced the dosing of the first patient in its global Phase 3 program for YCANTH (VP-102) to treat common warts, a condition affecting 22 million U.S. patients with no FDA-approved prescription therapies. This milestone follows promising Phase 2 COVE-1 study results showing 51% complete clearance of warts, indicating YCANTH's potential to become the first approved treatment for common warts in the U.S. and Japan. The company views this as a significant step for YCANTH's label expansion, offering substantial commercial and licensing opportunities.
